0001209191-16-147486.txt : 20161031
0001209191-16-147486.hdr.sgml : 20161031
20161031165035
ACCESSION NUMBER: 0001209191-16-147486
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161031
FILED AS OF DATE: 20161031
DATE AS OF CHANGE: 20161031
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001481512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262908274
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B14301
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (617) 401-4060
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B14301
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KOLLURI KRISHNA KITTU
CENTRAL INDEX KEY: 0001270521
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37926
FILM NUMBER: 161962215
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-10-31
0
0001481512
Ra Pharmaceuticals, Inc.
RARX
0001270521
KOLLURI KRISHNA KITTU
1954 GREENSPRING DRIVE
SUITE 600
TIMONIUM
MD
21093
0
0
1
0
Common Stock
2016-10-31
4
X
0
80658
0.07
A
80658
I
See Note 2
Common Stock
2016-10-31
4
S
0
435
13.00
D
80223
I
See Note 2
Common Stock
2016-10-31
4
C
0
1778227
A
1858450
I
See Note 2
Common Stock
2016-10-31
4
C
0
669951
A
2528401
I
See Note 2
Common Stock
2016-10-31
4
C
0
623210
A
3151611
I
See Note 2
Common Stock
2016-10-31
4
P
0
338462
13.00
A
3490073
I
See Note 2
Warrants to Purchase Common Stock
0.07
2016-10-31
4
X
0
80658
0.00
D
2022-04-01
Common Stock
80658
0
I
See Note 2
Series A Preferred Stock
2016-10-31
4
C
0
12447605
0.00
D
Common Stock
1778227
0
I
See Note 2
Series B-1 Preferred Stock
2016-10-31
4
C
0
4689657
0.00
D
Common Stock
669951
0
I
See Note 2
Series B-2 Preferred Stock
2016-10-31
4
C
0
4362472
0.00
D
Common Stock
623210
0
I
See Note 2
The Warrants automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 435 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 80,223 shares, after deducting the aggregate exercise price.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.
Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
/s/ Sasha Keough, attorney-in-fact
2016-10-31